Information Provided By:
Fly News Breaks for October 16, 2019
Oct 16, 2019 | 16:58 EDT
BofA/Merrill analyst Geoff Meacham reinstated coverage of Pfizer with a Neutral rating and $37 price target, saying that he believes the company's near-term pipeline is priced into shares and that he needs additional clarity on the pipeline.
News For PFE From the Last 2 Days
Feb 19, 2020 | 07:05 EST
Optinose (OPTN) announced the appointment of Victor Clavelli as chief commercial officer. Clavelli joins Optinose from Pfizer (PFE) where, in the course of an accomplished 20-year career, he held leadership roles including marketing, sales, and regulatory affairs. Most recently, he served as the North American President for Inflammation and Immunology with responsibility for a portfolio spanning topical, small molecule oral, and biologic agents.